Previous Close | 5.84 |
Open | 5.96 |
Bid | 5.83 x 400 |
Ask | 5.91 x 100 |
Day's Range | 5.77 - 6.12 |
52 Week Range | 1.57 - 8.19 |
Volume | |
Avg. Volume | 245,896 |
Market Cap | 254.449M |
Beta (5Y Monthly) | 0.71 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -1.05 |
Earnings Date | N/A |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 12.50 |
Werewolf Therapeutics (HOWL) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
WTX-518, a conditionally activated IL-18 INDUKINETM molecule that resists suppression by IL-18BP, led to complete tumor regressions in preclinical models WTX-712, a conditionally activated IL-21 INDUKINETM molecule has potent antitumor activity in preclinical models with a differentiated immune activation mechanism WATERTOWN, Mass., April 05, 2024 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the d
PREDATOR protein engineering technology allows for the expansion of INDUKINE™ molecules beyond oncology targets into new applications across a range of immunology targets, including inflammatory bowel diseaseWATERTOWN, Mass., April 04, 2024 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate the body’s immune system for the t